SOLICITATION NOTICE
66 -- Purchase of Genetic analysis of lymphoid malignancies with NextSeqTM 500 Sequencing V System
- Notice Date
- 5/6/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- N02RC46038-62
- Archive Date
- 6/7/2014
- Point of Contact
- Tiffany D. Kittrell, Phone: 2402765434
- E-Mail Address
-
Tiffany.kittrell@nih.gov
(Tiffany.kittrell@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room1E144, Bethesda, MD 20892 USA Description: The National Cancer Institute (NCI), Center for Cancer Research plans to procure on a sole source basis from Illumina Inc. at 5200 Illumina Way San Diego, CA 92122 for a NextSeqTM 500 Sequencing V System. The products herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b) (2) and FAR 13.501 (a)(1)(ii).The North American Industry Classification System Code is 334516 and the business size standard in 500. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire green products or services under this procurement. Delivery shall be made within 4 weeks of contract award. The Staudt laboratory at NCI performs a number of different genomics methodologies to discover oncogenic mechanisms in lymphoma, all of which require high-throughput DNA sequencing. Specifically, the laboratory developed loss-of-function genetic screens to discover new molecular targets in cancer using libraries of small hairpin RNAs (shRNAs) that mediate RNA interference (RNAi). This approach provides an unbiased screen for genes that regulate the proliferation and survival of cancer cells, pointing to new directions for therapeutic attack. Current efforts are aimed at whole genome screening for essential genes in a B cell and T cell lymphomas using both RNAi and CRISPR technologies. These experiments are analyzed using high-throughput DNA sequencing to identify which of the 50,000-150,000 vectors in our RNAi and CRISPR libraries confer a phenotype when introduced into lymphoma cells. The laboratory utilizes whole genome, whole exome and whole transcriptome cancer gene resequencing as a useful adjunct to RNAi screening, often identifying recurrent somatic mutations that account for the addiction of cancer cells to particular regulatory pathways. The laboratory developed an analytic pipeline to discover mutations using high-throughput RNA resequencing (RNA-seq), exome sequencing and whole genome sequencing. The NCI has extensive experience conducting high-throughput sequencing experiments using Illumina platforms. The laboratory has completed over 500 RNA-seq samples, 300 ChIP-seq samples and 266 exome-seq samples. To date, these analyses have been performed in a sequencing core using the Illumina HiSeq platform. To facilitate and accelerate this type of research in the future, the NCI requires an Illumina NextSeq 500 machine to increase the turnaround time compared to the Illumina HiSeq 2000 platform. The NextSeq platform delivers sequences in one day versus six days for the HiSeq 2000 platform. To ensure the continuity of ongoing experiments, NCI must continue to use an Illumina platform for three related reasons. First, NCI must be sure that the sequencing results in the future can be analyzed in combination with the sequencing data already in hand. Other sequencing technologies use different molecular mechanisms for sequencing and different analytics that leads to platform-specific sequencing artifacts. Therefore, in order to insure comparability of new sequencing data with our extensive database of sequencing in lymphoma, NCI has to continue to use an Illumina platform. Otherwise, NCI would risk contaminating analyses by platform-specific sequencing artifacts. Second, it is important that the libraries that are constructed for sequencing on a NextSeq 500 platform can be used directly on a HiSeq 2000. Finally, all of the proprietary analytic pipelines that NCI has developed for RNA-seq, exome-seq, and whole genome-seq are geared to use data provided in an Illumina format and would have to be completely recoded to use data from another type of sequencing machine. Salient Characteristics: • Scalability from 20-120 Gb in a single run to support a broad range of applications and study sizes • The ability to perform runs, including onboard cluster generation, in 12-30 hours • Must have fully automated onboard cluster generation to enable prepped libraries to be loaded directly onto the instrument • Must have SBS chemistry with single-base extension enables accurate sequencing of homopolymers • Must have fully automated paired-end sequencing Illumina Inc. is the only known manufacturer of a NextSeqTM 500 Sequencing V system with the above salient characteristics. This is not a solicitation for competitive quotations. However, if any interested party, especially a small business, believes they can meet the above requirement, they may submit a statement of capabilities and or quote. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on May 23, 2014. Electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed to (240) -276-5401 or emailed to Tiffany Kittrell, Contract Specialist, at Tiffany.kittrell@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC46038-62 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/N02RC46038-62/listing.html)
- Record
- SN03358406-W 20140508/140506234906-40dc5c2953864d5d0423dde5ef0a8c0d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |